{
    "Authorities": [
        {
            "Organization": "FDA",
            "Standards": [
                {
                    "Name": "SENDIG",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "3.0"
                },
                {
                    "Name": "SENDIG",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "3.1"
                },
                {
                    "Name": "SENDIG",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "3.1.1"
                },
                {
                    "Name": "SENDIG-GENETOX",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "1.0"
                },
                {
                    "Name": "SENDIG-DART",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "1.1"
                },
                {
                    "Name": "SENDIG-DART",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "1.2"
                },
                {
                    "Name": "SENDIG-AR",
                    "References": [
                        {
                            "Citations": [
                                {
                                    "Cited_Guidance": "For findings in MISTRESC using the NEOPLASM controlled terminology list, malignancy status in MIRESCAT should align with any benign or malignant designation in NEOPLASM. ",
                                    "Document": "FDA",
                                    "Section": "FDAB085"
                                }
                            ],
                            "Origin": "FDA Business Rules",
                            "Rule_Identifier": {
                                "Id": "FB8501",
                                "Version": "1"
                            },
                            "Version": "1.5"
                        }
                    ],
                    "Version": "1.0"
                }
            ]
        }
    ],
    "Check": {
        "any": [
            {
                "all": [
                    {
                        "name": "MISTRESC",
                        "operator": "contains",
                        "value": "BENIGN"
                    },
                    {
                        "name": "MIRESCAT",
                        "operator": "not_equal_to",
                        "value": "BENIGN"
                    }
                ]
            },
            {
                "all": [
                    {
                        "name": "MISTRESC",
                        "operator": "contains",
                        "value": "MALIGNANT"
                    },
                    {
                        "name": "MIRESCAT",
                        "operator": "is_not_contained_by",
                        "value": [
                            "MALIGNANT",
                            "METASTATIC"
                        ]
                    }
                ]
            }
        ]
    },
    "Core": {
        "Status": "Published",
        "Version": "1",
        "Id": "CORE-000618"
    },
    "Description": "The value in MISTRESC using the NEOPLASM CT must match the value in MIRESCAT",
    "Executability": "Fully Executable",
    "Outcome": {
        "Message": "The value in MISTRESC using the NEOPLASM CT does not match the value in MIRESCAT"
    },
    "Rule_Type": "Record Data",
    "Scope": {
        "Classes": {
            "Include": [
                "FINDINGS"
            ]
        },
        "Domains": {
            "Include": [
                "MI"
            ]
        }
    },
    "Sensitivity": "Record"
}